NO2399993T3 - - Google Patents

Info

Publication number
NO2399993T3
NO2399993T3 NO10743584A NO10743584A NO2399993T3 NO 2399993 T3 NO2399993 T3 NO 2399993T3 NO 10743584 A NO10743584 A NO 10743584A NO 10743584 A NO10743584 A NO 10743584A NO 2399993 T3 NO2399993 T3 NO 2399993T3
Authority
NO
Norway
Application number
NO10743584A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2399993T3 publication Critical patent/NO2399993T3/no

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO10743584A 2009-02-20 2010-02-19 NO2399993T3 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009037750 2009-02-20
PCT/JP2010/001100 WO2010095455A1 (fr) 2009-02-20 2010-02-19 Streptavidine hypo-immunogène et son utilisation

Publications (1)

Publication Number Publication Date
NO2399993T3 true NO2399993T3 (fr) 2018-02-17

Family

ID=42633742

Family Applications (1)

Application Number Title Priority Date Filing Date
NO10743584A NO2399993T3 (fr) 2009-02-20 2010-02-19

Country Status (7)

Country Link
US (1) US8546537B2 (fr)
EP (1) EP2399993B1 (fr)
JP (1) JP5472754B2 (fr)
CN (1) CN102325884B (fr)
CA (1) CA2753048C (fr)
NO (1) NO2399993T3 (fr)
WO (1) WO2010095455A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10065996B2 (en) * 2012-11-16 2018-09-04 Iba Gmbh Streptavidin muteins and methods of using them
JP6178586B2 (ja) * 2013-02-20 2017-08-09 サヴィッド・セラピューティックス株式会社 ビオチン改変体、ストレプトアビジン変異体およびそれらの利用
EP3109252B1 (fr) 2014-02-18 2020-12-30 Savid Therapeutics Inc. Biotine modifiée, mutant de streptavidine et leur utilisation
EP3353290A1 (fr) * 2015-09-23 2018-08-01 European Molecular Biology Laboratory Streptavidine résistant aux protéases
WO2018097239A1 (fr) 2016-11-25 2018-05-31 サヴィッド・セラピューティックス株式会社 Agent d'élimination
US20210214376A1 (en) 2018-05-30 2021-07-15 The University Of Tokyo Halogenated biotin-modified dimer and use thereof
WO2021210573A1 (fr) 2020-04-14 2021-10-21 国立大学法人 東京大学 Dimère modifié par de la biotine et son utilisation
WO2022094609A1 (fr) 2020-10-30 2022-05-05 Speer Tod Agents thérapeutiques à base d'oligonucléotides et utilisations associées
EP4382609A1 (fr) 2021-07-29 2024-06-12 The University of Tokyo Protéine de fusion entre une molécule de liaison à l'antigène et un variant de streptavidine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4135543A1 (de) 1991-10-28 1993-04-29 Boehringer Mannheim Gmbh Rekombinantes core-streptavidin
US5608060A (en) 1992-06-09 1997-03-04 Neorx Corporation Biotinidase-resistant biotin-DOTA conjugates
US6022951A (en) 1995-04-11 2000-02-08 Univ Boston Streptavidin mutants
HUP0000542A3 (en) * 1997-02-10 2002-02-28 Ca Minister Agriculture & Food Transgenic potatoes having reduced levels of alpha glucan l-or h-type tuber phosphorylase activity with reduced cold-sweetening
JP2003501096A (ja) 1999-06-07 2003-01-14 ネオルクス コーポレイション ストレプトアビジン発現性遺伝子融合およびその使用方法
US20030143233A1 (en) 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US7148051B2 (en) * 2004-08-16 2006-12-12 E. I. Du Pont De Nemours And Company Production of 3-hydroxycarboxylic acid using nitrilase
JP5117765B2 (ja) 2007-05-28 2013-01-16 国立大学法人 東京大学 抗ｒｏｂｏ１抗体を含むｐｅｔ用腫瘍診断剤

Also Published As

Publication number Publication date
CA2753048C (fr) 2015-11-03
CA2753048A1 (fr) 2010-08-26
CN102325884B (zh) 2013-11-20
JPWO2010095455A1 (ja) 2012-08-23
EP2399993A9 (fr) 2012-07-18
EP2399993B1 (fr) 2017-09-20
US8546537B2 (en) 2013-10-01
CN102325884A (zh) 2012-01-18
EP2399993A1 (fr) 2011-12-28
WO2010095455A1 (fr) 2010-08-26
US20120039879A1 (en) 2012-02-16
JP5472754B2 (ja) 2014-04-16
EP2399993A4 (fr) 2013-07-03

Similar Documents

Publication Publication Date Title
BR112012012396A2 (fr)
BR112012008267A2 (fr)
BR112012003062A2 (fr)
BR112012008195A2 (fr)
BR112012000607A2 (fr)
BRPI0924307A2 (fr)
BR122021004633A2 (fr)
BR112012003080A2 (fr)
BR122017024704A2 (fr)
BR112012012487A2 (fr)
BR112012000665A2 (fr)
BR112012003853A2 (fr)
BR112012009797A2 (fr)
BR112012009446A2 (fr)
BR112012009703A2 (fr)
BR112012010357A2 (fr)
BR112012007656A2 (fr)
BR112012001263A2 (fr)
BR122019005883A2 (fr)
BR112012002627A2 (fr)
BR112012000159A2 (fr)
BRPI0924534A2 (fr)
BR112012014856A2 (fr)
BR112012007672A2 (fr)
BR112012007654A2 (fr)